Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + XELOX in Resectable Gastric/GEJ Cancer
NCT06506292Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06506292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506292.